查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827443

甲状腺癌药物市场按癌症类型、治疗方式、药物类型、给药方法和最终用户划分－2025-2032 年全球预测

Thyroid Cancer Drugs Market by Cancer Type, Treatment Modality, Drug Type, Mode Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年甲状腺癌药物市场规模将成长至 21.1444 亿美元，复合年增长率为 11.40%。

主要市场统计数据
基准年2024年 8.9096亿美元
预计2025年 9.9483亿美元
预测年份：2032年 2,114,440,000美元
复合年增长率（%） 11.40%

为策略决策者提供关于重塑甲状腺癌治疗格局的临床、商业和营运驱动因素的全面概述

甲状腺癌治疗领域正在经历快速的科学和临床变革，新的治疗方法正在重塑临床路径和相关人员的期望。本执行摘要旨在帮助读者了解甲状腺癌治疗领域的最新进展，涵盖治疗方法、产品类别和最终用户动态，并概述其对製造商、付款方、医疗保健提供者和临床研究人员的战略意义。

本书以疾病异质性和临床紧迫性的简明框架为开端，阐述了当代治疗组合及其推动变革的力量，包括监管核准、真实世界证据的生成以及医疗服务模式的转变。本书重点介绍了分子标靶疗法、免疫肿瘤药物、手术和放射性碘等成熟治疗方法之间的相互作用，并强调了多学科治疗决策如何依赖日益复杂的生物标记和基因组资讯。

重要的是，引言还强调了伴随科学进步的商业性和营运考虑，从供应链弹性到患者获取途径，从而为甲状腺癌治疗的策略规划和投资优先奠定基础。

精准诊断、监管灵活性和门诊护理的趋势如何融合，从而改变甲状腺癌的治疗模式和相关人员的角色

过去几年，甲状腺癌的治疗模式已从相对静态的治疗模式转变为以动态创新和治疗多样化为特征的模式。精准诊断和分子分层强调了标靶治疗的重要性，使临床医生能够根据肿瘤的突变特征和抗药性模式製定治疗方法。因此，多激酶抑制剂和选择性标靶药物的临床作用不断扩大，同时，针对具有挑战性的组织学亚型的免疫疗法联合治疗也日益受到探索。

随着科学的进步，法律规范也随之调整，以适应加速核准、有条件核准以及生物标誌物定义人群驱动的扩大上市许可。卫生系统正在透过投资多学科肿瘤委员会和基因组检测基础设施来应对这些变化，从而影响转诊模式和治疗顺序。此外，口服肿瘤药物和门诊病人治疗方案的成熟正在影响剂量、依从性和长期患者管理，使治疗不再局限于住院。

简而言之，精准医疗、监管灵活性和医疗保健服务重组的整合正在推动变革性转变，为创新疗法创造机会，也为製造商和医疗保健提供者带来商业挑战。

评估2025年关税主导的供应链重组及其对甲状腺癌药物采购、临床营运和取得策略的下游影响

2025年关税的实施和贸易政策的调整为全球医药供应链带来了新的变量，并对营运和策略产生了显着的影响。对于通常依赖复杂原料药采购和跨境生产的甲状腺癌治疗药物而言，进口关税的提高凸显了供应链规划和双重筹资策略的重要性。这些累积效应促使人们重新关注如何重新评估采购惯例并优化生产布局，以减轻关税波动的影响。

此外，关税也强化了提高成本和定价策略透明度的必要性。企业越来越多地将潜在的贸易相关成本压力纳入采购合约和长期供应商伙伴关係中。临床试验物流也受到影响，临床试验赞助者在调整其场地选择和临床实验药物分销计划，以减少与海关相关的延误，并确保患者能够持续获得临床实验药物。

最后，这些不利因素正促使相关人员加快对近岸製造、供应弹性计画和合作协定模式的投资。这些调整旨在确保治疗的可获得性，保障患者获得药物，同时在不断变化的关税环境下保持可预测的交货时间表。

详细的細項分析将癌症组织学、治疗方式、药物类别、给药途径和最终用户动态与商业化和临床策略要务联繫起来

基于细分的洞察揭示了细微的模式，可为产品开发、上市规划和临床定位提供参考。我们基于癌症类型的分析涵盖甲状腺未分化癌 (ATC)、滤泡性甲状腺癌 (FTC)、许尔特尔细胞癌、甲状腺髓样癌 (MTC) 和甲状腺乳头状癌 (PTC)，重点关注它们独特的自然病程和治疗需求，从而驱动不同的临床重点和循证策略。我们根据治疗方式，研究了化疗、免疫疗法、放射性碘治疗、手术、标靶多激酶疗法和甲状腺刺激素(TSH) 抑制疗法，并展示了特定治疗方式的价值提案如何影响药物的采用、报销途径和跨专业协作。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 高选择性RET激酶抑制剂的出现改善了特异性患者的治疗
  • 整合液态生物检体基因组分析用于甲状腺癌的早期检测和治疗监测
  • 第二代多激酶抑制剂治疗放射性碘难治性甲状腺癌的核准和市场渗透
  • 开发结合 BRAF 抑制剂和免疫疗法的联合治疗以克服甲状腺癌的抗药性
  • 扩大患者可及性计画将促进新兴市场采用昂贵的甲状腺癌标靶治疗
  • 针对新型抗原的CAR-T细胞疗法在治疗未分化甲状腺癌的进展
  • 胜肽受体放射性核种治疗进行性甲状腺髓样癌的监管核准
  • 采用真实世界证据研究证明新型甲状腺癌治疗方法的有效性与安全性

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 甲状腺癌治疗药物市场（依癌症类型）

  • 未分化甲状腺癌（ATC）
  • 滤泡性甲状腺癌（FTC）
  • 赫特尔细胞癌
  • 甲状腺髓样癌（MTC）
  • 甲状腺乳突癌（PTC）

9. 甲状腺癌药物市场（依治疗方法）

  • 化疗
  • 免疫疗法
  • 放射性碘治疗
  • 外科手术
  • 标靶多激酶治疗
  • 甲状腺刺激素（TSH）抑制治疗

第 10 章 甲状腺癌药物市场（依药物类型）

  • 化疗药物
  • 荷尔蒙疗法药物
  • 免疫疗法
  • 标靶治疗药物

第11章 甲状腺癌药物市场依给药方式

  • 注射
    • 预填充式注射器
    • 管瓶
  • 口服
    • 胶囊
    • 药片

第 12 章 甲状腺癌药物市场（依最终使用者）

  • 居家照护环境
  • 医院
  • 肿瘤诊所
  • 研究机构

第十三章 甲状腺癌药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 甲状腺癌药物市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 甲状腺癌药物市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Eisai Co., Ltd.
    • Exelixis, Inc.
    • Bayer AG
    • AstraZeneca PLC
    • Blueprint Medicines Corporation
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
Product Code: MRR-434CCDA052BE

The Thyroid Cancer Drugs Market is projected to grow by USD 2,114.44 million at a CAGR of 11.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 890.96 million
Estimated Year [2025] USD 994.83 million
Forecast Year [2032] USD 2,114.44 million
CAGR (%) 11.40%

Comprehensive overview of clinical, commercial, and operational drivers reshaping the thyroid cancer treatment landscape for strategic decision-makers

The therapeutic landscape for thyroid cancer is undergoing rapid scientific and clinical evolution, with novel modalities reshaping clinical pathways and stakeholder expectations. This executive summary sets out to orient readers to the current state of play across treatment approaches, product classes, and end-user dynamics, and to outline strategic implications for manufacturers, payers, providers, and clinical researchers.

Beginning with a concise framing of disease heterogeneity and clinical urgency, the narrative moves through the contemporary therapeutic mix and the forces driving change, including regulatory approvals, real-world evidence generation, and shifts in care delivery. Emphasis is given to the interplay between targeted molecular therapies, immuno-oncology agents, and established modalities such as surgery and radioiodine, underscoring how multidisciplinary treatment decisions now rely on increasingly precise biomarker and genomic information.

Importantly, the introduction also highlights commercial and operational considerations that accompany scientific progress - from supply chain resilience to patient access pathways - setting the context for the deeper analytical sections that follow. This establishes the foundation for informed strategic planning and investment prioritization in thyroid cancer therapeutics.

How precision diagnostics, regulatory flexibility, and outpatient care trends are converging to transform thyroid cancer treatment paradigms and stakeholder roles

Across the past several years, the thyroid cancer landscape has shifted from a relatively static treatment paradigm to one characterized by dynamic innovation and therapeutic diversification. Precision diagnostics and molecular stratification have elevated the importance of targeted therapies, enabling clinicians to tailor treatment regimens to tumor mutation profiles and resistance patterns. Consequently, the clinical role of multikinase inhibitors and selective targeted agents has expanded, while immunotherapy combinations are increasingly explored for difficult-to-treat histologies.

Parallel to scientific advances, regulatory frameworks have adapted to accommodate accelerated approval pathways, conditional authorizations, and label expansions driven by biomarker-defined cohorts. Health systems are responding to these changes by investing in multidisciplinary tumor boards and genomic testing infrastructure, which in turn influence referral patterns and treatment sequencing. Additionally, the maturation of oral onco-pharmaceuticals and outpatient-centered regimens is shifting care away from inpatient settings, with implications for administration, adherence, and long-term patient management.

In short, transformative shifts are being driven by a convergence of precision medicine, regulatory flexibility, and care-delivery realignment, creating both opportunities for innovative therapeutics and operational challenges for manufacturers and providers alike.

Assessment of 2025 tariff-driven supply chain recalibrations and their downstream effects on procurement, clinical operations, and access strategies for thyroid cancer therapies

The imposition of tariffs and trade policy adjustments in 2025 introduced new variables into the global pharmaceutical supply chain with measurable operational and strategic consequences. For thyroid cancer therapeutics, which often rely on complex active pharmaceutical ingredient sourcing and cross-border manufacturing, increased import duties have amplified the importance of supply chain mapping and dual-sourcing strategies. The cumulative effect has been a re-evaluation of procurement practices and a renewed focus on manufacturing footprint optimization to mitigate exposure to tariff volatility.

Moreover, tariffs have reinforced the need for greater transparency in costing and pricing strategy. Organizations are increasingly factoring potential trade-related cost pressures into procurement contracts and long-term supplier partnerships. Clinical trial logistics have also been impacted, with sponsors adjusting trial site selection and investigational medicinal product distribution plans to reduce customs-related delays and ensure continuity of patient access to investigational therapies.

Finally, in response to these headwinds, stakeholders have accelerated investments in near-shore manufacturing, supply resiliency programs, and collaborative contracting models. These adaptations aim to preserve therapeutic availability and protect patient access while maintaining predictable delivery timelines in a changing tariff environment.

Deep segmentation analysis linking cancer histology, treatment modality, drug class, administration route, and end-user dynamics to commercialization and clinical strategy imperatives

Segmentation-based insights reveal nuanced patterns that inform product development, market access planning, and clinical positioning. Based on Cancer Type, the analysis covers Anaplastic Thyroid Cancer (ATC), Follicular Thyroid Cancer (FTC), Hurthle Cell Carcinoma, Medullary Thyroid Cancer (MTC), and Papillary Thyroid Cancer (PTC), highlighting the distinct natural histories and therapeutic needs that dictate differential clinical priorities and evidence generation strategies. Based on Treatment Modality, the study examines Chemotherapy, Immunotherapy, Radioiodine Therapy, Surgery, Targeted Multikinase Therapy, and Thyroid Stimulating Hormone (TSH) Suppression Therapy, demonstrating how modality-specific value propositions influence adoption, reimbursement pathways, and cross-specialty coordination.

Based on Drug Type, distinctions among Chemotherapy Agents, Hormone Therapy Drugs, Immunotherapy Drugs, and Targeted Therapy Drugs underscore the varying development timelines, safety profiles, and companion diagnostic dependencies that sponsors must navigate. Based on Mode Of Administration, injectable and oral forms are evaluated, with the Injectable further disaggregated into Pre-Filled Syringes and Vials and the Oral subdivided into Capsules and Tablets; this distinction influences manufacturing complexity, patient adherence patterns, and distribution logistics. Based on End User, the report addresses Homecare Settings, Hospitals, Oncology Clinics, and Research Organizations, each representing unique purchasing behaviors, clinical workflows, and post-market evidence opportunities.

Taken together, these segmentation lenses demonstrate that effective commercialization strategies require an integrated approach that aligns clinical development with administration logistics and end-user dynamics, while also prioritizing evidence generation that resonates with the decision criteria of diverse stakeholder groups.

Region-specific clinical, regulatory, and access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine adoption and market entry strategies

Regional intelligence highlights distinct regulatory, clinical, and access dynamics that shape therapeutic strategy across global markets. In the Americas, the regulatory environment emphasizes expedited review pathways and robust real-world evidence collection, which supports accelerated uptake for biomarker-driven therapies and creates opportunities for outcome-based contracting and managed entry agreements. Clinical practice in this region tends to integrate multidisciplinary care delivery models and advanced genomic testing, driving early adoption of precision therapeutics and oral treatment regimens.

In Europe, Middle East & Africa, fragmentation across regulatory frameworks and reimbursement systems necessitates tailored market entry tactics that account for country-level HTA processes, variability in diagnostic infrastructure, and differences in hospital procurement. Stakeholders should prioritize evidence packages that align with regional HTA endpoints and invest in local clinician engagement to navigate heterogeneous payer environments. Additionally, capacity constraints in parts of the region can influence access to advanced modalities such as radioiodine therapy and immuno-oncology combinations.

In Asia-Pacific, diverse regulatory timelines and accelerating investment in oncology research create a complex but opportunity-rich landscape. Many jurisdictions in this region are expanding molecular testing and decentralizing cancer care, which in turn supports broader population access to targeted and oral therapies. Strategic partnerships with local manufacturers, attention to pricing and reimbursement nuances, and investment in regional real-world evidence generation will be critical to achieving sustainable access and uptake across Asia-Pacific markets.

Competitive and corporate strategies that define success in thyroid oncology including pipeline prioritization, diagnostics partnerships, and outcome-driven commercialization capabilities

Company-level dynamics are central to competitive positioning and therapeutic differentiation in thyroid oncology. Leading pharmaceutical and biotechnology companies are advancing pipelines through a combination of internal discovery, strategic collaborations, and targeted acquisitions, with particular emphasis on agents that address unmet needs in aggressive or refractory histologies. Across the competitive set, successful companies are those that couple robust clinical programs with clear companion diagnostic strategies and post-authorization evidence generation plans.

Commercially, organizations that invest in integrated launch capabilities - combining payer engagement, clinician education, and patient support services - are better positioned to accelerate uptake of new therapies. Operational excellence in supply chain management and manufacturing scale-up is equally critical to avoid launch disruptions and to support global demand. Partnerships between biopharma firms and diagnostic providers are increasingly common, reflecting the need to bundle testing and treatment pathways to optimize clinical outcomes and payer value assessments.

Finally, companies demonstrating agility in pricing models and contracting arrangements, including risk-sharing agreements and value-based frameworks, are more likely to secure access in environments where payers demand demonstrable outcomes. These company-level approaches collectively define who will convert clinical innovation into sustained therapeutic impact.

Practical and high-impact recommendations for manufacturers and payers to align diagnostics, supply resilience, patient support, and flexible contracting for sustained therapeutic success

Industry leaders should adopt a set of targeted actions to translate scientific progress into sustainable patient impact. Prioritize integration of molecular diagnostics into clinical development plans early, aligning study endpoints with payer-relevant outcomes to streamline reimbursement discussions. Simultaneously, invest in supply chain redundancies and near-shore manufacturing options to mitigate tariff and trade-related disruptions while preserving timely access to critical therapies.

Moreover, foster collaborations across the ecosystem by forming partnerships with diagnostic companies, academic centers, and regional distributors to expedite adoption and to build localized evidence. Enhance patient support programs to address adherence and administration barriers, particularly as oral regimens and homecare delivery models become more prevalent. From a commercial perspective, develop flexible contracting strategies that allow for outcome-based elements and adaptive pricing aligned with real-world performance.

Finally, embed agile decision-making processes into R&D and commercial operations so that learnings from early real-world deployments can rapidly inform label expansions, combination therapy studies, and lifecycle management. These actions will help organizations convert innovation into measurable clinical and commercial success.

Robust mixed-methods research framework combining expert interviews, secondary evidence review, and validation techniques to ensure actionable and credible insights

The research approach underpinning this analysis combines structured primary research with comprehensive secondary synthesis and rigorous validation. Primary inputs were derived from in-depth interviews with clinical experts, senior clinicians across relevant specialties, supply chain leaders, and payers to capture first-hand perspectives on treatment patterns, access hurdles, and operational realities. Secondary synthesis incorporated peer-reviewed literature, regulatory documentation, clinical trial registries, and publicly available product labels to contextualize therapeutic mechanisms and evidence maturations.

Data validation involved triangulating stakeholder interviews with clinical guideline trends and regulatory actions to ensure consistency and to identify divergences between trial settings and real-world practice. The methodology also employed scenario analysis to stress-test assumptions around supply disruptions, policy shifts, and treatment pathway changes. Where applicable, patient pathway mapping was used to surface friction points in diagnosis, treatment initiation, and long-term follow-up.

Collectively, these methodological elements ensure that the insights presented are grounded in real-world clinical practice and operational feasibility, providing a robust foundation for strategic decision-making by industry and clinical stakeholders.

Strategic synthesis of clinical, commercial, and operational imperatives that stakeholders must address to convert innovation into improved patient outcomes

In conclusion, the thyroid cancer therapeutic arena is transitioning toward a more personalized, evidence-driven paradigm in which diagnostics, therapeutics, and care delivery are tightly interdependent. Precision medicine advances and new regulatory pathways are enabling faster clinical translation, but they also demand sophisticated commercialization and operational strategies to ensure patient access and to sustain clinical benefit. Moreover, external dynamics such as tariff-induced supply chain risks and regional policy heterogeneity underscore the importance of adaptive planning and collaborative partnerships.

For stakeholders seeking to lead in this environment, success will hinge on aligning clinical development with payer-relevant evidence, building resilient manufacturing and distribution networks, and investing in end-user engagement across hospitals, clinics, and homecare settings. By doing so, manufacturers, providers, and policymakers can collectively improve outcomes for diverse thyroid cancer patient populations while navigating the complex commercial and operational landscape.

This summary provides a strategic vantage point for executives and clinicians to prioritize initiatives that will have the greatest impact on patient care and organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of highly selective RET kinase inhibitors improving patient-specific therapy
  • 5.2. Integration of liquid biopsy genomic profiling in early detection and treatment monitoring for thyroid cancer
  • 5.3. Approval and market uptake of second-generation multikinase inhibitors for radioiodine refractory thyroid carcinoma
  • 5.4. Development of combination regimens pairing BRAF inhibitors with immunotherapy to overcome resistance in thyroid cancer
  • 5.5. Expansion of patient access programs driving uptake of costly targeted therapies in emerging markets for thyroid cancer treatment
  • 5.6. Advances in CAR T cell therapies targeting novel antigens in anaplastic thyroid carcinoma management
  • 5.7. Regulatory approvals of peptide receptor radionuclide therapy for advanced medullary thyroid carcinoma patients
  • 5.8. Adoption of real-world evidence studies informing efficacy and safety of new thyroid cancer treatment modalities

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Thyroid Cancer Drugs Market, by Cancer Type

  • 8.1. Anaplastic Thyroid Cancer (ATC)
  • 8.2. Follicular Thyroid Cancer (FTC)
  • 8.3. Hurthle Cell Carcinoma
  • 8.4. Medullary Thyroid Cancer (MTC)
  • 8.5. Papillary Thyroid Cancer (PTC)

9. Thyroid Cancer Drugs Market, by Treatment Modality

  • 9.1. Chemotherapy
  • 9.2. Immunotherapy
  • 9.3. Radioiodine Therapy
  • 9.4. Surgery
  • 9.5. Targeted Multikinase Therapy
  • 9.6. Thyroid Stimulating Hormone (TSH) Suppression Therapy

10. Thyroid Cancer Drugs Market, by Drug Type

  • 10.1. Chemotherapy Agents
  • 10.2. Hormone Therapy Drugs
  • 10.3. Immunotherapy Drugs
  • 10.4. Targeted Therapy Drugs

11. Thyroid Cancer Drugs Market, by Mode Of Administration

  • 11.1. Injectable
    • 11.1.1. Pre-Filled Syringes
    • 11.1.2. Vials
  • 11.2. Oral
    • 11.2.1. Capsules
    • 11.2.2. Tablets

12. Thyroid Cancer Drugs Market, by End User

  • 12.1. Homecare Settings
  • 12.2. Hospitals
  • 12.3. Oncology Clinics
  • 12.4. Research Organizations

13. Thyroid Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Thyroid Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Thyroid Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Eisai Co., Ltd.
    • 16.3.2. Exelixis, Inc.
    • 16.3.3. Bayer AG
    • 16.3.4. AstraZeneca PLC
    • 16.3.5. Blueprint Medicines Corporation
    • 16.3.6. Eli Lilly and Company
    • 16.3.7. Merck & Co., Inc.
    • 16.3.8. Merck KGaA
    • 16.3.9. Novartis AG
    • 16.3.10. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. THYROID CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. THYROID CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. THYROID CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL THYROID CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ANAPLASTIC THYROID CANCER (ATC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY FOLLICULAR THYROID CANCER (FTC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HURTHLE CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MEDULLARY THYROID CANCER (MTC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PAPILLARY THYROID CANCER (PTC), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RADIOIODINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED MULTIKINASE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) SUPPRESSION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY PRE-FILLED SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL THYROID CANCER DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN THYROID CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. GCC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. GCC THYROID CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. GCC THYROID CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. G